Showing results (1021-1030 of 1,994) with videos related to

Sort By:
Pageof 200
Archivos De Prevencion De Riesgos Laborales|July 6, 2013
[Four year follow-up of a screening program for prostate cancer in workers]Luis Reinoso-Barbero, Ramón Díaz-Garrido, Montserrat Piñaga-Solé, et al.
Journal of Neuro-Oncology|July 1, 1993
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumorsD J Stewart, Z Grahovac, H Hugenholtz, et al.
International Journal of Spine Surgery|January 24, 2020
Sagittal Spinal and Pelvic Parameters in Patients With Scheuermann's Disease: A Preliminary StudyS Samuel Bederman, Saif Farhan, Xiaobang Hu, et al.
Transfusion|September 2, 2022
Implementation strategy for complete pathogen reduction technology treated apheresis platelet inventoryElaine Shu, Concepcion Dela Cruz Batilo, Harry Sussmann, et al.
The Journal of Head Trauma Rehabilitation|December 29, 2015
Utility of the Neurobehavioral Symptom Inventory As an Outcome Measure: A VA TBI Model Systems StudyHeather G Belanger, Marc A Silva, Alison J Donnell, et al.
Ecotoxicology and Environmental Safety|September 10, 2016
Aquatic toxicity structure-activity relationships for the zwitterionic surfactant alkyl dimethyl amine oxide to several aquatic species and a resulting species sensitivity distributionScott E Belanger, Jessica L Brill, Jane M Rawlings, et al.
Health Research Policy and Systems|July 31, 2016
Development of training for medicines-oriented policymakers to apply evidenceH L Colquhoun, E Helis, D Lowe, et al.
Rehabilitation Psychology|July 3, 2013
Pilot of a novel intervention for postconcussive symptoms in active duty, veterans, and civiliansEmily G King, Tracy S Kretzmer, Rodney D Vanderploeg, et al.
European Journal of Pharmacology|May 7, 2022
Dequalinium chloride is an antagonists of α7 nicotinic acetylcholine receptorsMatthieu G Belanger-Coast, Mei Zhang, Vladislav Bugay, et al.
Future Virology|December 5, 2023
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19Arantxa Horga, Daniel R Kuritzkes, John J Kowalczyk, et al.
Pageof 200